Abstract
In the multi-disciplinary treatment of head and neck tumors, anti-cancer chemotherapy was evaluated by the survival rate, response rate and preservation of function and shape. Chemotherapy significantly improved the survival rates in cervical esophageal, hypopharyngeal and maxillary cancer and malignant lymphoma in stage II. A new regimen of Pepleomycin, Vincristine, Endoxan, Mitomycin-C, Predonine, 5-Fu and Adriacin showed a better than partial response in 42% of the patients. Functional preservation with combined chemotherapy was observed only in maxillary cancer.Chemosensitivities for head and neck malignant tumors were measured in order to select useful drugs. Although no concrete merit of these tests has yet been achieved, inoperable recurrent carcinoma or maxillary cancer will be treated by more selective anti-cancer drugs. Furthermore, photoradiation therapy with hematoporphyrin derivatives will become a useful modality for head and neck tumors in the near future, because this technique does not destroy normal tissue.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
